Inspire (company)

Tackling the Roadblocks of Mental Health Services, Finally

Retrieved on: 
Tuesday, October 19, 2021
Inspire (company), Psychiatry, Leadership, Mental health, Benefit corporation, CEO, Private practice, Lists of diseases, Topical steroid withdrawal, Technology, COVID-19, United States Public Health Service, Pharmaceutical industry, Management

The modern mental health app proves to have the largest variety of services available from therapy, life coaching, psychiatry, counseling, mentorship, and more.

Key Points: 
  • The modern mental health app proves to have the largest variety of services available from therapy, life coaching, psychiatry, counseling, mentorship, and more.
  • The newly established company has surfaced to destigmatize mental health, eliminate roadblocks to get help and give access to care through their groundbreaking app, Therapute.
  • With many Americans not having access to mental health providers due to the impact of the COVID-19 pandemic, the demand for online professional support has never been higher.
  • Learn more regarding Therapute and how the app eliminates barriers surrounding mental health in the United States at their national launch event, November 20th.

National Cancer Research Institute endorses CBD Science Group as they pioneer Real World research into Cancer pain

Retrieved on: 
Thursday, September 2, 2021
NCRI, NHS England, Friends, Prescription, Population, Comment, Real, Legislation, National Institute for Health and Care Excellence, COVID, Pain, Cannabinoid, Group, Cancer, Science, Nature, Intention, Family, National Cancer Research Institute, RWE, Research, Disease, NICE, Fear, Inspire (company), NHS, Chronic pain, Cannabis, Patient, Partnership, Ill, Oncology, Cancer pain, National Institute, Pharmaceutical industry

LONDON, Sept. 2, 2021 /PRNewswire/ -- CBD Science Group (the 'Company') is delighted to announce a highly sought-after endorsement from the National Cancer Research Institute (NCRI), which has seen the NCRI Living With and Beyond Cancer (LWBC) Executive Group endorse the company's Real World Evidence (RWE) study into the role that cannabinoids can play in treating cancer related pain. The development will give hope to cancer patients world wide as the treatment and management of cancer pain continues to be a major burden on patients and families.

Key Points: 
  • The development will give hope to cancer patients world wide as the treatment and management of cancer pain continues to be a major burden on patients and families.
  • CBD Science Group is a biopharmaceutical company who are enabling accelerated access to treatment through a pragmatic Real World Evidence, peer-reviewed clinical trial.
  • This partnership will further progress CBD Science Group towards our objective of realising the advantages of cannabinoids in fulfilling this urgent need of suffering patients.
  • CBD Science Group undertakes no obligation to comment on analyses, expectations or statements made by third-parties in respect of CBD Science Group, its securities, or financial or operating results (as applicable).

National Cancer Research Institute endorses CBD Science Group as they pioneer Real World research into Cancer pain

Retrieved on: 
Thursday, September 2, 2021
NCRI, NHS England, Friends, Prescription, Population, Comment, Real, Legislation, National Institute for Health and Care Excellence, COVID, Pain, Cannabinoid, Group, Cancer, Science, Nature, Intention, Family, RWE, National Cancer Research Institute, Research, Disease, NICE, Fear, Inspire (company), NHS, Chronic pain, Cannabis, Patient, Partnership, Ill, Oncology, Cancer pain, National Institute, Pharmaceutical industry

LONDON, Sept. 2, 2021 /PRNewswire/ -- CBD Science Group (the 'Company') is delighted to announce a highly sought-after endorsement from the National Cancer Research Institute (NCRI), which has seen the NCRI Living With and Beyond Cancer (LWBC) Executive Group endorse the company's Real World Evidence (RWE) study into the role that cannabinoids can play in treating cancer related pain. The development will give hope to cancer patients world wide as the treatment and management of cancer pain continues to be a major burden on patients and families.

Key Points: 
  • CBD Science Group is delighted to confirm that it's Real World Evidence (RWE) Study has been endorsed by the National Cancer Research Institute (NCRI) Living With and Beyond Cancer (LWBC) Executive Group.
  • LONDON, Sept. 2, 2021 /PRNewswire/ --CBD Science Group (the 'Company') is delighted to announce a highly sought-after endorsement from the National Cancer Research Institute (NCRI), which has seen the NCRI Living With and Beyond Cancer (LWBC) Executive Group endorse the company's Real World Evidence (RWE) study into the role that cannabinoids can play in treating cancer related pain.
  • The development will give hope to cancer patients world wide as the treatment and management of cancer pain continues to be a major burden on patients and families.
  • CBD Science Group is a biopharmaceutical company who are enabling accelerated access to treatment through a pragmatic Real World Evidence, peer-reviewed clinical trial.